Single and Multiple Ascending Dose Study of KN-002

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma; Part 3 is a repeat dose in patients with moderate to severe asthma and Part 4 is a repeat dose in patients with COPD.

Inclusion Criteria:

• Male or female, 18 - 55 years old
• Willing and able to give informed consent and comply with the study
• Body mass index (BMI) 18 to 32 kg/m2 and weighs at least 50 kg
• Women of child bearing potential must have a negative pregnancy test and use a highly efficient birth control method
• Pre-bronchodilator FEV1 ≥ 70 and ≥80% for Part 1 and Part 2 participants, respectively
• Pre-Bronchodilator FEV1 ≥50% predicted and ≤100% for Part 3
• Post Bronchodilator FEV1 ≥40 and ≤ 85% for Part 4

Exclusion Criteria:

• Clinically significant laboratory test abnormalities
• Clinically significant abnormal blood pressure and/or pulse rate
• Resting ECG clinically significant abnormalities
• Respiratory tract infection within 6 weeks of screening
• Positive test for active COVID-19 within 2 days prior to administration of IMP